Mark S Sulkowski
Overview
Explore the profile of Mark S Sulkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
196
Citations
9864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Khalili M, King W, Kleiner D, Chung R, Bhan A, Ghany M, et al.
Clin Infect Dis
. 2021 Oct;
74(11):1914-1924.
PMID: 34698347
Background: Fatty liver disease (FLD) and hepatitis B virus (HBV) infection occur commonly in human immunodeficiency virus (HIV). FLD resolution is associated with improvement in lipoproteins in HIV-uninfected patients. We...
22.
Hammami M, Kohli R, Woreta T, Sulkowski M, Hamilton J, Toman L, et al.
ACG Case Rep J
. 2021 Sep;
8(5):e00582.
PMID: 34549060
Liver transplantation (LT) for patients with hepatitis D virus (HDV) and hepatitis B virus (HBV) coinfection is uncommon in the United States. Previous case reports described poor outcomes when hepatitis...
23.
Ward K, Falade-Nwulia O, Moon J, Sutcliffe C, Brinkley S, Haselhuhn T, et al.
J Infect Dis
. 2021 Sep;
225(5):903-911.
PMID: 34543417
Background: Eliminating hepatitis C virus (HCV) will require effective treatment delivery to persons with substance use disorders (SUDs). We evaluated the relationship between ledipasvir/sofosbuvir treatment persistence (receiving 84 tablets), adherence,...
24.
Sulkowski M, Moon J, Sherman K, Morelli G, Darling J, Muir A, et al.
Hepatology
. 2021 Jul;
74(6):2952-2964.
PMID: 34255381
Background And Aims: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. Approach And...
25.
Peters M, Kottilil S, Terrault N, Amara D, Husson J, Huprikar S, et al.
Am J Transplant
. 2020 Dec;
21(5):1780-1788.
PMID: 33277801
Direct-acting antiviral (DAA) therapy has transformed the management of human immunodeficiency virus (HIV) and hepatitis C (HCV) coinfected patients with advanced liver disease. STOP-Coinfection was a multicenter prospective and retrospective,...
26.
Falade-Nwulia O, Sulkowski M
J Infect Dis
. 2020 Nov;
222(Suppl 9):S745-S757.
PMID: 33245350
The availability of safe, efficacious, oral direct-acting antivirals (DAAs) have ushered in a new era of hepatitis C treatment with potential to eliminate hepatitis C as a public health threat....
27.
Balagopal A, Grudda T, Ribeiro R, Saad Y, Hwang H, Quinn J, et al.
JCI Insight
. 2020 Oct;
5(19).
PMID: 33004689
There is no cure for the more than 270 million people chronically infected with HBV. Nucleos(t)ide analogs (NUCs), the mainstay of anti-HBV treatment, block HBV reverse transcription. NUCs do not...
28.
Irvin R, Ntiri-Reid B, Kleinman M, Agee T, Hitt J, Anaedozie O, et al.
J Viral Hepat
. 2020 Jul;
27(12):1388-1395.
PMID: 32671942
In 2014, trained healthcare provider capacity was insufficient to deliver care to an estimated 70 000 persons in Maryland with chronic hepatitis C virus (HCV) infection. The goal of Maryland...
29.
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine
Verma M, Chu J, Salama J, Faiz M, Eweje F, Gwynne D, et al.
Proc Natl Acad Sci U S A
. 2020 May;
117(22):11987-11994.
PMID: 32424082
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis worldwide and kills more Americans than 59 other infections, including HIV and tuberculosis, combined. While direct-acting antiviral (DAA)...
30.
Anthony D, Sulkowski M, Smeaton L, Damjanovska S, Shive C, Kowal C, et al.
J Infect Dis
. 2020 May;
222(8):1334-1344.
PMID: 32406487
Background: Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a...